Patterns of care and outcome for patients with glioblastoma diagnosed during 2008–2010 in Spain
Open Access
- 3 March 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (6), 797-805
- https://doi.org/10.1093/neuonc/not013
Abstract
To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008–2010 in Spain. Retrospective analysis of clinical, therapeutic, and survival data collected through filled questionnaires from patients with histologically confirmed GBM diagnosed in 19 Spanish hospitals. We identified 834 patients (23% aged >70 years). Surgical resection was achieved in 66% of patients, although the extent of surgery was confirmed by postoperative MRI in only 41%. There were major postoperative complications in 14% of patients, and age was the only independent predictor (Odds ratio [OR], 1.03; 95% confidence interval [CI],1.01–1.05; P = .006). After surgery, 57% received radiotherapy (RT) with concomitant and adjuvant temozolomide, 21% received other regimens, and 22% were not further treated. In patients treated with surgical resection, RT, and chemotherapy (n = 396), initiation of RT ≤42 days was associated with longer progression-free survival (hazard ratio [HR], 0.8; 95% CI, 0.64–0.99; P = .042) but not with overall survival (HR, 0.79; 95% CI, 0.62–1.00; P = .055). Only 32% of patients older than 70 years received RT with concomitant and adjuvant temozolomide. The median survival in this group was 10.8 months (95% CI, 6.8–14.9 months), compared with 17.0 months (95% CI, 15.5–18.4 months; P = .034) among younger patients with GBM treated with the same regimen. In a community setting, 57% of all patients with GBM and only 32% of older patients received RT with concomitant and adjuvant temozolomide. In patients with surgical resection who were eligible for chemoradiation, initiation of RT ≤42 days was associated with better progression-free survival.Keywords
This publication has 38 references indexed in Scilit:
- Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006Neuro-Oncology, 2012
- Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients – Early Results of a Phase II TrialFrontiers in Oncology, 2012
- Adult glioblastoma multiforme survival in the temozolomide era: A population‐based analysis of Surveillance, Epidemiology, and End Results registriesCancer, 2011
- Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004Neuro-Oncology, 2010
- Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastomaCancer, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group DatabaseJournal of Clinical Oncology, 2009
- Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastomaNeuro-Oncology, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005